Journals and Databases

Start a new search

Healthcare Databases Advanced Search | Help

 

Searched: Antiretroviral Therapy, Highly Active. Total records matched: 3006

Resources searched: MEDLINE from PubMed

  1. 1. African Ancestry Influences CCR5 -2459G>A Genotype-Associated Virologic Success of Highly Active Antiretroviral Therapy.

    Author(s): Cheruvu VK, Igo RP Jr, Jurevic RJ, Serre D, Zimmerman PA, Rodriguez B, Mehlotra RK

    Citation: Journal of acquired immune deficiency syndromes (1999), 01 May 2014, vol./is. 66/1(102-7), 1525-4135

    Publication Date: 01 May 2014

    Source: MEDLINE from PubMed

  2. 2. The prevalence of antiretroviral multidrug resistance in highly active antiretroviral therapy-treated patients with HIV/AIDS between 2004 and 2009 in South Korea.

    Author(s): Choi JY, Kwon OK, Choi BS, Kee MK, Park M, Kim SS

    Citation: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 21 February 2014, 1386-6532

    Publication Date: 21 February 2014

    Source: MEDLINE from PubMed

  3. 3. Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy-era.

    Author(s): Munier AL, de Lastours V, Porcher R, Donay JL, Pons JL, Molina JM

    Citation: International journal of STD & AIDS, 27 March 2014, 0956-4624

    Publication Date: 27 March 2014

    Source: MEDLINE from PubMed

  4. 4. An AIDS-defining neoplasm in a 30-year-old man on highly active antiretroviral therapy: a forgotten diagnosis?

    Author(s): Russell MD, Singh-Ranger D, Crosbie J

    Citation: BMJ case reports, 26 March 2014,

    Publication Date: 26 March 2014

    Source: MEDLINE from PubMed

  5. 5. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study.

    Author(s): Enawgaw B, Alem M, Addis Z, Melku M

    Citation: BMC hematology, 25 March 2014, vol./is. 14/1(8),

    Publication Date: 25 March 2014

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at BioMedCentral

  6. 6. Treatment Response in Association with Adherence Patterns to Highly Active Antiretroviral Therapy in Pediatric Patients with Perinatally Acquired HIV Infection.

    Author(s): Malhotra A, Whitley-Williams PN, Gaur S, Petrova A

    Citation: Journal of the International Association of Providers of AIDS Care, 17 March 2014, 2325-9574

    Publication Date: 17 March 2014

    Source: MEDLINE from PubMed

  7. 7. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.

    Author(s): Zoufaly A, Kiepe J, Hertling S, Hüfner A, Degen O, Feldt T, Schmiedel S, Kurowski M, van Lunzen J

    Citation: HIV medicine, 24 February 2014, 1464-2662

    Publication Date: 24 February 2014

    Source: MEDLINE from PubMed

  8. 8. Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia.

    Author(s): Hejazi N, Huang MS, Lin KG, Choong LC

    Citation: Global journal of health science, 01 December 2013, vol./is. 6/2(58-71), 1916-9736

    Publication Date: 01 December 2013

    Source: MEDLINE from PubMed

  9. 9. Adherence to highly active antiretroviral therapy in a tertiary care hospital in West Bengal, India.

    Author(s): Saha R, Saha I, Sarkar AP, Das DK, Misra R, Bhattacharya K, Roy RN, Bhattacharya A

    Citation: Singapore medical journal, February 2014, vol./is. 55/2(92-8), 0037-5675

    Publication Date: February 2014

    Source: MEDLINE from PubMed

  10. 10. Incidence and associated factors of pulmonary tuberculosis in HIV-infected children after highly active antiretroviral therapy (HAART) in China: a retrospective study.

    Author(s): Mu W, Zhao Y, Sun X, Ma Y, Yu L, Liu X, Zhao D, Dou Z, Fang H, Zhang F

    Citation: AIDS care, 10 February 2014, 0954-0121

    Publication Date: 10 February 2014

    Source: MEDLINE from PubMed

  11. 11. Assessing baseline religious practices and beliefs to predict adherence to highly active antiretroviral therapy among HIV-infected persons.

    Author(s): Vyas KJ, Limneos J, Qin H, Mathews WC

    Citation: AIDS care, 06 February 2014, 0954-0121

    Publication Date: 06 February 2014

    Source: MEDLINE from PubMed

  12. 12. Management of noninfectious diarrhea associated with HIV and highly active antiretroviral therapy.

    Author(s): Macarthur RD

    Citation: The American journal of managed care, September 2013, vol./is. 19/12 Suppl(s238-45), 1088-0224

    Publication Date: September 2013

    Source: MEDLINE from PubMed

  13. 13. The Association between Yang-Deficient Constitution and Clinical Outcome of Highly Active Antiretroviral Therapy on People Living with HIV.

    Author(s): Cen Y, Leung RK, Zhang F, Jia W, Zhang J, Tan X, Xu F

    Citation: Evidence-based complementary and alternative medicine : eCAM, 2013(201857), 1741-427X

    Publication Date: 2013

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at National Library of Medicine

  14. 14. Vitamin A and beta-carotene concentrations in adults with HIV/AIDS on highly active antiretroviral therapy.

    Author(s): Kaio DJ, Rondó PH, Souza JM, Firmino AV, Luzia LA, Segurado AA

    Citation: Journal of nutritional science and vitaminology, 2013, vol./is. 59/6(496-502), 0301-4800

    Publication Date: 2013

    Source: MEDLINE from PubMed

  15. 15. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

    Author(s): Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF

    Citation: Cancer, 15 April 2014, vol./is. 120/8(1194-202), 0008-543X

    Publication Date: 15 April 2014

    Source: MEDLINE from PubMed

  16. 16. Sclerosing cholangitis by cytomegalovirus in highly active antiretroviral therapy era.

    Author(s): Hidalgo Tenorio C, Blasco Morente G

    Citation: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, October 2013, vol./is. 105/9(557-560), 1130-0108

    Publication Date: October 2013

    Source: MEDLINE from PubMed

  17. 17. Effect of highly active antiretroviral therapy (HAART) and menopause on risk of progression of cervical dysplasia in human immune-deficiency virus- (HIV-) infected women.

    Author(s): Kim SC, Messing S, Shah K, Luque AE

    Citation: Infectious diseases in obstetrics and gynecology, 2013(784718), 1064-7449

    Publication Date: 2013

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at National Library of Medicine

  18. 18. Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.

    Author(s): Ngemu EK, Khayeka-Wandabwa C, Kweka EJ, Choge JK, Anino E, Oyoo-Okoth E

    Citation: BMC research notes, 21 January 2014(52),

    Publication Date: 21 January 2014

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at National Library of Medicine

    Available in fulltext at BioMedCentral

  19. 19. Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.

    Author(s): Wanless RS, Rugină S, Ruţă SM, Dumitru IM, Cernat RC, Schwarzwald HL, Calles NR, Schutze GE, Schweitzer AM, Draper HR, Kline MW

    Citation: Germs, 01 September 2013, vol./is. 3/3(90-5),

    Publication Date: 01 September 2013

    Source: MEDLINE from PubMed

  20. 20. Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.

    Author(s): Slama L, Li X, Brown T, Jacobson LP, Pialoux G, Macatangay B, Bolan RK, Phair J, Palella FJ Jr

    Citation: Journal of acquired immune deficiency syndromes (1999), 01 January 2014, vol./is. 65/1(57-64), 1525-4135

    Publication Date: 01 January 2014

    Source: MEDLINE from PubMed

  21. 21. Sex Differences in HIV Outcomes in the Highly Active Antiretroviral Therapy Era: A Systematic Review.

    Author(s): Castilho JL, Melekhin VV, Sterling TR

    Citation: AIDS research and human retroviruses, 07 February 2014, 0889-2229

    Publication Date: 07 February 2014

    Source: MEDLINE from PubMed

  22. 22. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.

    Author(s): Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A

    Citation: Therapeutics and clinical risk management, 2014(9-15), 1176-6336

    Publication Date: 2014

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at National Library of Medicine

  23. 23. Early Highly Active Antiretroviral Therapy Enhances B-cell Longevity: A 5 Year Follow Up.

    Author(s): Cagigi A, Rinaldi S, Cotugno N, Manno EC, Santilli V, Mora N, Zangari P, Aquilani A, Tchidjou KH, Giaquinto C, Bernardi S, Rossi P, Palma P

    Citation: The Pediatric infectious disease journal, May 2014, vol./is. 33/5(e126-31), 0891-3668

    Publication Date: May 2014

    Source: MEDLINE from PubMed

  24. 24. Predictors of attrition and immunological failure in HIV-1 patients on highly active antiretroviral therapy from different healthcare settings in Mozambique.

    Author(s): Palladino C, Briz V, Bellón JM, Bártolo I, Carvalho P, Camacho R, Muñoz-Fernández MÁ, Bastos R, Manuel R, Casanovas J, Taveira N

    Citation: PloS one, 2013, vol./is. 8/12(e82718),

    Publication Date: 2013

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at National Library of Medicine

  25. 25. Effects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study.

    Author(s): Liu C, Wang C, Glesby MJ, D'souza G, French A, Minkoff H, Maurer T, Karim R, Young M

    Citation: AIDS research and therapy, 27 December 2013, vol./is. 10/1(34),

    Publication Date: 27 December 2013

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at BioMedCentral

    Available in fulltext at National Library of Medicine

  26. 26. Direct monthly highly active antiretroviral therapy supply - a method to increase patient's adherence and outcome. Experience of one AIDS center in Israel.

    Author(s): Elbirt D, Asher I, Mahlev-Guri K, Bezalel-Rozenberg S, Werner B, Cohen Y, Sthoeger Z

    Citation: International journal of STD & AIDS, 09 January 2014, 0956-4624

    Publication Date: 09 January 2014

    Source: MEDLINE from PubMed

  27. 27. Impact of Highly Active Antiretroviral Therapy on the Natural History of Cervical Precancerous Lesions: A 17-Year Institutional Longitudinal Cohort Study.

    Author(s): Patrelli TS, Gizzo S, Peri F, Franchi L, Volpi L, Esposito F, Pedrazzi G, Antoni AD, Modena AB

    Citation: Reproductive sciences (Thousand Oaks, Calif.), 13 December 2013, 1933-7191

    Publication Date: 13 December 2013

    Source: MEDLINE from PubMed

  28. 28. Opportunistic diseases in HIV-infected patients in Gabon following the administration of highly active antiretroviral therapy: a retrospective study.

    Author(s): Okome-Nkoumou M, Guiyedi V, Ondounda M, Efire N, Clevenbergh P, Dibo M, Dzeing-Ella A

    Citation: The American journal of tropical medicine and hygiene, February 2014, vol./is. 90/2(211-5), 0002-9637

    Publication Date: February 2014

    Source: MEDLINE from PubMed

  29. 29. Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada.

    Author(s): Palmer AK, Cescon A, Chan K, Cooper C, Raboud JM, Miller CL, Burchell AN, Klein MB, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Loutfy MR

    Citation: Journal of the International Association of Providers of AIDS Care, January 2014, vol./is. 13/1(56-62), 2325-9574

    Publication Date: January 2014

    Source: MEDLINE from PubMed

  30. 30. Insulin resistance and lipid Profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.

    Author(s): Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V

    Citation: Journal of pediatric endocrinology & metabolism : JPEM, 21 November 2013(1-10), 0334-018X

    Publication Date: 21 November 2013

    Source: MEDLINE from PubMed

  31. 31. [Multi-centered, randomized controlled clinical study on Chinese medicine formula particles for hyperlipidaemia associated with highly active antiretroviral therapy].

    Author(s): Ni L, Wang RB, Guo HJ, Tan XH, Sun LJ, Zheng YH, Duan CY, Hu DQ, Wang WJ, Wang YG, Zhao HX

    Citation: Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, August 2013, vol./is. 38/15(2443-7), 1001-5302

    Publication Date: August 2013

    Source: MEDLINE from PubMed

  32. 32. The VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy.

    Author(s): Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, Okulicz JF, Bavaro M, Weintrob AC, Justice AC, Agan BK

    Citation: Journal of acquired immune deficiency syndromes (1999), 01 February 2014, vol./is. 65/2(226-30), 1525-4135

    Publication Date: 01 February 2014

    Source: MEDLINE from PubMed

  33. 33. Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa.

    Author(s): Ketseoglou I, Lukhwareni A, Steegen K, Carmona S, Stevens WS, Papathanasopoulos MA

    Citation: AIDS research and human retroviruses, March 2014, vol./is. 30/3(289-93), 0889-2229

    Publication Date: March 2014

    Source: MEDLINE from PubMed

  34. 34. The impacts of first line highly active antiretroviral therapy on serum selenium, CD4 count and body mass index: a cross sectional and short prospective study.

    Author(s): Akinboro AO, Onayemi O, Ayodele OE, Mejiuni AD, Atiba AS

    Citation: The Pan African medical journal, 2013(97),

    Publication Date: 2013

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at National Library of Medicine

  35. 35. NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy.

    Author(s): Sennepin A, Baychelier F, Guihot A, Nel I, Fang RH, Calin R, Katlama C, Simon A, Crouzet J, Debré P, Vieillard V

    Citation: AIDS (London, England), 31 July 2013, vol./is. 27/12(1857-66), 0269-9370

    Publication Date: 31 July 2013

    Source: MEDLINE from PubMed

  36. 36. African ethnicity can influence immunological responses to highly active antiretroviral therapy and immunological success at 48 months: a retrospective pilot study.

    Author(s): Guillaume C, N'Guyen Y, Brodard V, Bani-Sadr F, Jaussaud R, Andreoletti L

    Citation: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, December 2013, vol./is. 17/12(e1259-62), 1201-9712

    Publication Date: December 2013

    Source: MEDLINE from PubMed

  37. 37. HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

    Author(s): Nosyk B, Min J, Lima VD, Yip B, Hogg RS, Montaner JS

    Citation: Journal of acquired immune deficiency syndromes (1999), 15 August 2013, vol./is. 63/5(653-9), 1525-4135

    Publication Date: 15 August 2013

    Source: MEDLINE from PubMed

  38. 38. The Effect of Depressive Symptoms and CD4 Count on Adherence to Highly Active Antiretroviral Therapy in Sub-Saharan Africa.

    Author(s): Memiah P, Shumba C, Etienne-Mesubi M, Agbor S, Hossain MB, Komba P, Niyang M, Biadgilign S

    Citation: Journal of the International Association of Providers of AIDS Care, 10 October 2013, 2325-9574

    Publication Date: 10 October 2013

    Source: MEDLINE from PubMed

  39. 39. Characteristics and Factors Associated with the Clinical Forms of Lipoatrophy during Highly Active Antiretroviral Therapy in Ouagadougou, Burkina Faso.

    Author(s): Guira O, Tiéno H, Yaméogo B, Diendéré AE, Korsaga N, Sagna Y, Zoungrana L, Diallo I, Traoré R, Drabo JY

    Citation: Journal of the International Association of Providers of AIDS Care, March 2014, vol./is. 13/2(184-7), 2325-9574

    Publication Date: March 2014

    Source: MEDLINE from PubMed

  40. 40. Toxoplasma encephalitis in an HIV-infected patient on highly active antiretroviral therapy despite sustained immune response.

    Author(s): Atreya AR, Arora S, Gadiraju VT, Martagon-Villamil J, Skiest DJ

    Citation: International journal of STD & AIDS, April 2014, vol./is. 25/5(383-6), 0956-4624

    Publication Date: April 2014

    Source: MEDLINE from PubMed

  41. 41. Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children.

    Author(s): Nesheim SR, Hardnett F, Wheeling JT, Siberry GK, Paul ME, Emmanuel P, Bohannon B, Dominguez K

    Citation: The Pediatric infectious disease journal, October 2013, vol./is. 32/10(1089-95), 0891-3668

    Publication Date: October 2013

    Source: MEDLINE from PubMed

  42. 42. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy.

    Author(s): Yang JJ, Tsai MS, Sun HY, Hsieh SM, Chen MY, Sheng WH, Chang SC

    Citation: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 21 September 2013, 1684-1182

    Publication Date: 21 September 2013

    Source: MEDLINE from PubMed

  43. 43. [Assessment on depressive status and the therapeutic effects of highly active antiretroviral therapy among anti-HIV-1(+) population].

    Author(s): Zhang L, Yang D, Zhao HX, Han N, Xiao J, Chen YF, Han Z, Li YM, Wei K, Zhang W, Gao GJ

    Citation: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, May 2013, vol./is. 34/5(461-3), 0254-6450

    Publication Date: May 2013

    Source: MEDLINE from PubMed

  44. 44. Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: a meta-analysis.

    Author(s): Tsiara CG, Nikolopoulos GK, Dimou NL, Bagos PG, Saroglou G, Velonakis E, Hatzakis A

    Citation: Journal of viral hepatitis, October 2013, vol./is. 20/10(715-24), 1352-0504

    Publication Date: October 2013

    Source: MEDLINE from PubMed

  45. 45. A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era.

    Author(s): Ramana KV, Sabitha V, Rao R

    Citation: Journal of clinical and diagnostic research : JCDR, July 2013, vol./is. 7/7(1332-5), 2249-782X

    Publication Date: July 2013

    Source: MEDLINE from PubMed

  46. 46. Reduction of maternal mortality with highly active antiretroviral therapy in a large cohort of HIV-infected pregnant women in Malawi and Mozambique.

    Author(s): Liotta G, Mancinelli S, Nielsen-Saines K, Gennaro E, Scarcella P, Magid NA, Germano P, Jere H, Guidotti G, Buonomo E, Ciccacci F, Palombi L, Marazzi MC

    Citation: PloS one, 2013, vol./is. 8/8(e71653),

    Publication Date: 2013

    Source: MEDLINE from PubMed

    Full Text:

    Available in fulltext at National Library of Medicine

  47. 47. Polyactin A increases CD4(+) T-cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy.

    Author(s): Su QJ, Li YZ, Liang FL, Xiao J, Deng X

    Citation: International journal of STD & AIDS, January 2014, vol./is. 25/1(24-8), 0956-4624

    Publication Date: January 2014

    Source: MEDLINE from PubMed

  48. 48. Non Protease Inhibitor-Based Highly Active Antiretroviral Therapy (HAART) improves micromineral status in HIV positive Nigerians.

    Author(s): Okwara EC, Meludu SC, Okwara JE, Enwere OO, Diwe KC, Amah UK, Ezeugwunne IP, Okwara EI

    Citation: Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria, 30 June 2013, vol./is. 28/1(105-7), 0794-859X

    Publication Date: 30 June 2013

    Source: MEDLINE from PubMed

  49. 49. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

    Author(s): Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI

    Citation: Vaccine, 01 October 2013, vol./is. 31/42(4782-90), 0264-410X

    Publication Date: 01 October 2013

    Source: MEDLINE from PubMed

  50. 50. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

    Author(s): Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D

    Citation: BJOG : an international journal of obstetrics and gynaecology, November 2013, vol./is. 120/12(1534-47), 1470-0328

    Publication Date: November 2013

    Source: MEDLINE from PubMed


Results Selected
No results selected.

Output Format
Choose output document format.
Display Format
Choose output fields.
Actions
Display, save or email results with selected fields and output formats.